Navigation Links
Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
Date:3/29/2011

LONDON, March 30, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology ("ASCO") Annual Meeting.  The meeting will take place in Chicago June 3-7, 2011.  Atu027, in clinical development for systemic cancer indications, is one of the most clinically advanced RNAi therapeutics in the area of oncology.  

Klaus Giese, Ph.D., chief scientific officer of Silence, and Dr. Dirk Strumberg, Professor of Medicine and Director, Department of Hematology and Medical Oncology, University of Bochum, Marienhospital Herne, the study's principal investigator, will present abstract #3057 titled "First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors."

The presentation will highlight data from Silence's ongoing, open label, single-centre, dose-finding Phase I study with Atu027 in subjects with advanced solid cancer.  Key findings presented will include safety, tolerability and pharmacokinetic data, as well as indications of antitumor activity.  Previously published preclinical data demonstrated that treatment with Atu027 prevented the spread of breast cancer to the lungs in preclinical models of cancer metastases, and interim data from the ongoing Phase I clinical trial suggests that Atu027 could have a similar therapeutic effect in humans.

"We are pleased to have our abstract accepted by ASCO and believe that presenting this data at such a prestigious scientific conference represents an important milestone in our efforts to translate our foundational RNAi technology into viable therapeutic products," said Philip Haworth
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
2. Silence Therapeutics Provides Year-end Update
3. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Silence Therapeutics Announces Board Changes
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
11. Osseon™ Therapeutics Introduces Osseoflex® BT Steerable Bone Tamp
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:5/24/2013)... to the new market research report “Micro Irrigation System ... by MarketsandMarkets, global micro irrigation system market expected to ... 2010 and is expected to reach $3,414.7 million by ... to 2016. , Browse:, , 150 ... 370 pages and in-depth Table Of Content ...
(Date:5/24/2013)... 24, 2013 Just about any bodyweight training ... Whitfield, a trainer based in Dallas, GA that uses a ... one pushup that is not used enough. , “The ... the standard pushup more challenging. By keeping your hands on ... the abs are being worked much harder than a standard ...
(Date:5/24/2013)... 2013 Child safety expert and author, ... end-of-year gifts for teachers that can "show appreciation for ... Van der Zande is the founder of Kidpower, a ... whose mission is to help people create cultures ... have an incredible impact on the emotional and physical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Patients who ... more likely to suffer from gastroesophageal reflux disease or ... reported in a study published today. , The article, ... Proximal Exposure as Measured by Hypopharyngeal Multichannel Intraluminal Impedance” ... could be of great importance to individuals who live ...
(Date:5/24/2013)... BroadConnect Telecom, the nation’s leading ... IT security solutions, present small to midsized businesses ... more than fifty percent (when compared to conventional ... Bundle Pricing. BroadConnect’s hosted Voice solutions are putting ... , Starting today, until the end of June ...
Breaking Medicine News(10 mins):Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 2Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 3Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 4Health News:West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough 2Health News:BroadConnect Is Offering New Hosted PBX Bundle Pricing for New Customers, Eliminating VoIP Adoption Barriers 2
... well-being, , FRIDAY, Sept. 25 (HealthDay News) -- The bad ... points. , The good news is that it appears that ... one expert believes that part of the reason why is ... United States and elsewhere. , That,s the view of discipline ...
... ... October 31 - Sunday, November 1. Practitioner Training: Friday, October 30 , ... Buffalo, NY (PRWEB) September 25, ... of 1 in 150 children in the U.S. have an Autism Spectrum Disorder (ASD), ...
... ... of New Emergency 911 Center , ... Pittsburgh, PA (PRWEB) September 25, 2009 -- synergIT ... San Francisco the firm,s ground-breaking renovation of Washington County,s Emergency 911 call center ...
... ... upgrades to iCodeRx, iDocs, and iCharts now allow healthcare organizations to fully integrate and ... information. , ... Beach, VA (PRWEB) - DOMA Technologies ( www.domaonline.com ) has launched the latest version ...
... diet and weight are shaped by their social class, according ... Council. Policymakers have long insisted on the importance ... is the first study to show how everyday practices and ... diet, weight and health of teenagers. ,It is evident ...
... modest advantage over non-surgical therapies, researchers say , THURSDAY, ... than non-surgical treatment for patients with carpal tunnel syndrome ... has found. , The study included 44 patients who ... such as hand therapy and ultrasound. A year after ...
Cached Medicine News:Health News:Spanking May Lower Kids' IQs 2Health News:Spanking May Lower Kids' IQs 3Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 2Health News:AutismOne & Autism Canada Present "CHANGING THE COURSE OF AUTISM IN CANADA 2009" University of Toronto 3Health News:synergIT Presents at VMworld 2009 in San Francisco 2Health News:synergIT Presents at VMworld 2009 in San Francisco 3Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 3Health News:Social background weighs heavily on teenage diet 2Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
... ENDOPATH Dilating Tip Trocar is a full-featured trocar ... a spring-loaded blade shield. The shield is designed ... internal structures from puncture or laceration once the ... integrated stability sleeve option is designed to enhance ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: